Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuya Inoue

Showing results (261-270 of 265) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 265 results.
Cancer Science|October 22, 2018
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaMakoto Nakagawa, Shuhei Fujita, Takuo Katsumoto, et al.
Acta Neuropathologica|February 12, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profilesKenji Fujimoto, Mai Honda-Kitahara, Naoko Hattori, et al.
Cancer Science|November 30, 2021
Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomasRintaro Noro, Kazufumi Honda, Kengo Nagashima, et al.
BJR Case Reports|January 20, 2026
Local control of locally advanced uterine sarcoma achieved by cervical brachytherapy with gel spacer following cyclic hypofractionated radiation therapy (QUAD shot) in a patient who refused surgeryYasuo Kosugi, Naoya Murakami, Tatsuki Karino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.
Pageof 27

Showing results (261-270 of 265) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 265 results.
Cancer Science|October 22, 2018
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myelomaMakoto Nakagawa, Shuhei Fujita, Takuo Katsumoto, et al.
Acta Neuropathologica|February 12, 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profilesKenji Fujimoto, Mai Honda-Kitahara, Naoko Hattori, et al.
Cancer Science|November 30, 2021
Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomasRintaro Noro, Kazufumi Honda, Kengo Nagashima, et al.
BJR Case Reports|January 20, 2026
Local control of locally advanced uterine sarcoma achieved by cervical brachytherapy with gel spacer following cyclic hypofractionated radiation therapy (QUAD shot) in a patient who refused surgeryYasuo Kosugi, Naoya Murakami, Tatsuki Karino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2023
Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II TrialIan E Krop, Norikazu Masuda, Toru Mukohara, et al.
Pageof 27